CTR9 [The Human Chemical-Genetic Interaction Map Project]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
======= CTR9 =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: CTR9
  * **<color #00a2e8>Official Name</color>**: CTR9 homolog, Paf1/RNA polymerase II complex component
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=9646|9646]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/Q6PD62|Q6PD62]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=CTR9&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20CTR9|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/609366|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**:  The protein encoded by this gene is a component of the PAF1 complex, which associates with RNA polymerase II and functions in transcriptional regulation and elongation. This complex also plays a role in the modification of histones. [provided by RefSeq, Oct 2016]. 
  * **<color #00a2e8>UniProt Summary</color>**:  Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non- phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both indepentently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of KMT2A/MLL1; it promotes leukemogenesis through association with KMT2A/MLL1-rearranged oncoproteins, such as KMT2A/MLL1-MLLT3/AF9 and KMT2A/MLL1-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Required for mono- and trimethylation on histone H3 'Lys-4' (H3K4me3) and dimethylation on histone H3 'Lys-79' (H3K4me3). Required for Hox gene transcription. Required for the trimethylation of histone H3 'Lys- 4' (H3K4me3) on genes involved in stem cell pluripotency; this function is synergistic with CXXC1 indicative for an involvement of the SET1 complex. Involved in transcriptional regulation of IL6-responsive genes and in JAK-STAT pathway; may regulate DNA- association of STAT3 (By similarity). {ECO:0000250, ECO:0000269|PubMed:16024656, ECO:0000269|PubMed:16307923, ECO:0000269|PubMed:19345177, ECO:0000269|PubMed:19952111, ECO:0000269|PubMed:20178742, ECO:0000269|PubMed:20541477, ECO:0000269|PubMed:21329879}.

<button type='default' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
No Pfam Domain information is available for this gene.
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|positive regulation of histone H3-K79 methylation|
|regulation of histone H3-K79 methylation|
|positive regulation of histone H2B ubiquitination|
|regulation of genetic imprinting|
|positive regulation of histone ubiquitination|
|regulation of histone H2B ubiquitination|
|inner cell mass cell differentiation|
|Cdc73/Paf1 complex|
|negative regulation of mRNA polyadenylation|
|negative regulation of mRNA 3-end processing|
|regulation of histone ubiquitination|
|histone H2B ubiquitination|
|endodermal cell fate commitment|
|histone H3-K4 trimethylation|
|trophectodermal cell differentiation|
|interleukin-6-mediated signaling pathway|
|positive regulation of histone H3-K4 methylation|
|blastocyst growth|
|positive regulation of transcription elongation from RNA polymerase II promoter|
|regulation of mRNA polyadenylation|
|transcriptionally active chromatin|
|hatching|
|organism emergence from protective structure|
|blastocyst hatching|
|regulation of histone H3-K4 methylation|
|negative regulation of mRNA processing|
|regulation of mRNA 3-end processing|
|cell fate commitment involved in formation of primary germ layer|
|peptidyl-lysine trimethylation|
|regulation of transcription elongation from RNA polymerase II promoter|
|histone monoubiquitination|
|positive regulation of DNA-templated transcription, elongation|
|RNA polymerase II complex binding|
|cellular response to interleukin-6|
|response to interleukin-6|
|SH2 domain binding|
|histone H3-K4 methylation|
|receptor signaling pathway via JAK-STAT|
|blastocyst formation|
|positive regulation of histone methylation|
|receptor signaling pathway via STAT|
|histone ubiquitination|
|endodermal cell differentiation|
|endoderm formation|
|regulation of DNA-templated transcription, elongation|
|protein monoubiquitination|
|regulation of histone methylation|
|histone lysine methylation|
|endoderm development|
|transcription elongation from RNA polymerase II promoter|
|negative regulation of myeloid cell differentiation|
|negative regulation of mRNA metabolic process|
|peptidyl-lysine methylation|
|DNA-templated transcription, elongation|
|positive regulation of histone modification|
|histone methylation|
|blastocyst development|
|positive regulation of chromatin organization|
|formation of primary germ layer|
|positive regulation of protein ubiquitination|
|positive regulation of protein modification by small protein conjugation or removal|
|protein alkylation|
|protein methylation|
|stem cell population maintenance|
|maintenance of cell number|
|negative regulation of hemopoiesis|
|regulation of mRNA processing|
|regulation of histone modification|
|gastrulation|
|positive regulation of chromosome organization|
|cellular response to lipopolysaccharide|
|regulation of chromatin organization|
|cellular response to molecule of bacterial origin|
|regulation of protein ubiquitination|
|cellular response to biotic stimulus|
|regulation of myeloid cell differentiation|
|regulation of protein modification by small protein conjugation or removal|
|cell fate commitment|
|macromolecule methylation|
|methylation|
|peptidyl-lysine modification|
|response to lipopolysaccharide|
|response to molecule of bacterial origin|
|regulation of mRNA metabolic process|
|regulation of chromosome organization|
|cell-cell signaling by wnt|
|Wnt signaling pathway|
|histone modification|
|covalent chromatin modification|
|in utero embryonic development|
|developmental growth|
|growth|
|nuclear speck|
|cell surface receptor signaling pathway involved in cell-cell signaling|
|negative regulation of immune system process|
|regulation of hemopoiesis|
|transcription by RNA polymerase II|
|cellular response to lipid|
|embryonic morphogenesis|
|positive regulation of organelle organization|
|chordate embryonic development|
|transcription, DNA-templated|
|nucleic acid-templated transcription|
|embryo development ending in birth or egg hatching|
|RNA biosynthetic process|
|cytokine-mediated signaling pathway|
|protein ubiquitination|
|response to bacterium|
|chromatin organization|
|negative regulation of cell differentiation|
|protein modification by small protein conjugation|
|response to lipid|
|negative regulation of transcription by RNA polymerase II|
|peptidyl-amino acid modification|
|anatomical structure formation involved in morphogenesis|
|negative regulation of developmental process|
|embryo development|
|protein modification by small protein conjugation or removal|
|cellular response to cytokine stimulus|
|cellular response to oxygen-containing compound|
|chromosome organization|
|nucleobase-containing compound biosynthetic process|
|response to cytokine|
|cell-cell signaling|
|heterocycle biosynthetic process|
|aromatic compound biosynthetic process|
|negative regulation of transcription, DNA-templated|
|negative regulation of multicellular organismal process|
|positive regulation of cellular component organization|
|positive regulation of transcription by RNA polymerase II|
|positive regulation of protein modification process|
|negative regulation of nucleic acid-templated transcription|
|negative regulation of RNA biosynthetic process|
|regulation of organelle organization|
|response to other organism|
|organic cyclic compound biosynthetic process|
|response to external biotic stimulus|
|response to biotic stimulus|
|negative regulation of RNA metabolic process|
|negative regulation of cellular macromolecule biosynthetic process|
|negative regulation of nucleobase-containing compound metabolic process|
|negative regulation of macromolecule biosynthetic process|
|negative regulation of cellular biosynthetic process|
|positive regulation of transcription, DNA-templated|
|negative regulation of biosynthetic process|
|response to oxygen-containing compound|
|positive regulation of cellular protein metabolic process|
|cellular nitrogen compound biosynthetic process|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|regulation of immune system process|
|RNA metabolic process|
|positive regulation of protein metabolic process|
|cellular macromolecule biosynthetic process|
|negative regulation of gene expression|
|positive regulation of RNA metabolic process|
|tissue development|
|macromolecule biosynthetic process|
|regulation of cell differentiation|
|regulation of protein modification process|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|gene expression|
|positive regulation of biosynthetic process|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='primary' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp499|LY2090314 0.003μM R08 exp499]]|-2.5|
|[[:results:exp431|Rotenone 0.07μM R08 exp431]]|-2.26|
|[[:results:exp435|JQ1 0.8μM R08 exp435]]|-2.22|
|[[:results:exp28|Pimelic-diphenylamide-106 5μM R00 exp28]]|-2.19|
|[[:results:exp244|SB743921 0.001μM R05 exp244]]|-2.18|
|[[:results:exp512|Olaparib 4μM R08 exp512]]|-2.08|
|[[:results:exp532|TIC10 10μM R08 exp532]]|-2.07|
|[[:results:exp531|THZ1 0.06μM R08 exp531]]|-1.98|
|[[:results:exp34|Rotenone 20μM R00 exp34]]|-1.97|
|[[:results:exp507|Monensin 0.3μM R08 exp507]]|-1.91|
|[[:results:exp503|Mitomycin-C 0.06μM R08 exp503]]|-1.9|
|[[:results:exp24|Nocodazole 0.2μM R00 exp24]]|-1.88|
|[[:results:exp515|PU-H71 1μM R08 exp515]]|-1.83|
|[[:results:exp350|Deferoxamine 11μM R07 exp350]]|-1.75|
|[[:results:exp529|Thimerosal 0.85μM R08 exp529]]|-1.74|
|[[:results:exp30|Rapamycin 10μM R00 exp30]]|1.8|
|[[:results:exp29|Rapamycin 1μM R00 exp29]]|1.85|
|[[:results:exp82|Torin1 0.08μM R02 exp82]]|1.88|
|[[:results:exp149|SB203580 25μM R03 exp149]]|1.89|
|[[:results:exp263|Aphidicolin 0.04μM R06 exp263]]|1.91|
|[[:results:exp423|Zebularine 20μM R07 exp423]]|1.92|
|[[:results:exp11|CCCP 1μM R00 exp11]]|2.01|
|[[:results:exp420|Tunicamycin 0.04 to 0.125μM  on day4 R07 exp420]]|2.19|
|[[:results:exp495|IWR1 50μM R08 exp495]]|2.22|
|[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|2.36|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
^Gene^Correlation^
|[[:human genes:c:cdc73|CDC73]]|0.581|
|[[:human genes:p:paf1|PAF1]]|0.537|
|[[:human genes:z:znf106|ZNF106]]|0.511|
|[[:human genes:n:narfl|NARFL]]|0.502|
|[[:human genes:r:rps9|RPS9]]|0.494|
|[[:human genes:p:psmd3|PSMD3]]|0.489|
|[[:human genes:o:orc1|ORC1]]|0.48|
|[[:human genes:m:mt1e|MT1E]]|0.479|
|[[:human genes:t:tbc1d3h|TBC1D3H]]|0.475|
|[[:human genes:p:pan3|PAN3]]|0.471|
|[[:human genes:t:tceb3c|TCEB3C]]|0.467|
|[[:human genes:r:rbm39|RBM39]]|0.463|
|[[:human genes:t:tceb3cl2|TCEB3CL2]]|0.461|
|[[:human genes:o:orc6|ORC6]]|0.46|
|[[:human genes:d:ddtl|DDTL]]|0.459|
|[[:human genes:d:dtl|DTL]]|0.453|
|[[:human genes:p:psma6|PSMA6]]|0.452|
|[[:human genes:t:tbc1d3c|TBC1D3C]]|0.452|
|[[:human genes:t:tbc1d3g|TBC1D3G]]|0.446|
|[[:human genes:s:sec13|SEC13]]|0.445|
|[[:human genes:a:atp13a1|ATP13A1]]|0.445|
|[[:human genes:v:vasn|VASN]]|0.443|
|[[:human genes:p:psmb4|PSMB4]]|0.44|
|[[:human genes:t:tceb3cl|TCEB3CL]]|0.439|
|[[:human genes:p:pola2|POLA2]]|0.436|
|[[:human genes:t:tpx2|TPX2]]|0.435|
|[[:human genes:p:psmc1|PSMC1]]|0.435|
|[[:human genes:i:igfn1|IGFN1]]|0.434|
|[[:human genes:p:ppm1d|PPM1D]]|0.433|
|[[:human genes:a:akirin2|AKIRIN2]]|0.432|
|[[:human genes:t:tbc1d3i|TBC1D3I]]|0.432|
|[[:human genes:p:psmd11|PSMD11]]|0.432|
|[[:human genes:t:tbc1d3e|TBC1D3E]]|0.431|
|[[:human genes:t:tbc1d3k|TBC1D3K]]|0.43|
|[[:human genes:t:tbc1d3l|TBC1D3L]]|0.43|
|[[:human genes:c:cdk8|CDK8]]|0.429|
|[[:human genes:n:nop16|NOP16]]|0.429|
|[[:human genes:p:psmd1|PSMD1]]|0.429|
|[[:human genes:i:ints8|INTS8]]|0.428|
|[[:human genes:h:hist2h3c|HIST2H3C]]|0.428|
|[[:human genes:s:slc4a1|SLC4A1]]|0.428|
|[[:human genes:c:ckap5|CKAP5]]|0.428|
|[[:human genes:h:hist2h3a|HIST2H3A]]|0.427|
|[[:human genes:c:c14orf93|C14orf93]]|0.427|
|[[:human genes:k:krt78|KRT78]]|0.424|
|[[:human genes:r:rpl35|RPL35]]|0.423|
|[[:human genes:b:brd2|BRD2]]|0.423|
|[[:human genes:x:xylt2|XYLT2]]|0.421|
|[[:human genes:c:cdca3|CDCA3]]|0.42|
|[[:human genes:c:chd4|CHD4]]|0.42|
|[[:human genes:i:ilf2|ILF2]]|0.42|
|[[:human genes:r:rpl6|RPL6]]|0.419|
|[[:human genes:n:nbpf10|NBPF10]]|0.419|
|[[:human genes:a:atxn1|ATXN1]]|0.418|
|[[:human genes:m:myo1h|MYO1H]]|0.417|
|[[:human genes:r:rrn3|RRN3]]|0.416|
|[[:human genes:r:rbm22|RBM22]]|0.416|
|[[:human genes:p:psmd14|PSMD14]]|0.416|
|[[:human genes:c:copg1|COPG1]]|0.415|
|[[:human genes:c:copa|COPA]]|0.415|
|[[:human genes:s:snrpa1|SNRPA1]]|0.414|
|[[:human genes:s:ssh2|SSH2]]|0.413|
|[[:human genes:f:fcn2|FCN2]]|0.411|
|[[:human genes:r:rad51|RAD51]]|0.41|
|[[:human genes:g:golga8o|GOLGA8O]]|0.41|
|[[:human genes:t:tfip11|TFIP11]]|0.41|
|[[:human genes:r:rps2|RPS2]]|0.409|
|[[:human genes:a:arcn1|ARCN1]]|0.409|
|[[:human genes:i:ints6|INTS6]]|0.409|
|[[:human genes:t:tbc1d3f|TBC1D3F]]|0.407|
|[[:human genes:r:rps12|RPS12]]|0.407|
|[[:human genes:w:wdr61|WDR61]]|0.407|
|[[:human genes:c:cep192|CEP192]]|0.407|
|[[:human genes:z:zfand5|ZFAND5]]|0.406|
|[[:human genes:t:twistnb|TWISTNB]]|0.405|
|[[:human genes:r:rpl38|RPL38]]|0.405|
|[[:human genes:t:traip|TRAIP]]|0.404|
|[[:human genes:a:aamp|AAMP]]|0.404|
|[[:human genes:r:rps28|RPS28]]|0.403|
|[[:human genes:s:sf3a2|SF3A2]]|0.403|
|[[:human genes:c:copb1|COPB1]]|0.403|
|[[:human genes:c:c2orf27b|C2orf27B]]|0.403|
|[[:human genes:p:pou2f1|POU2F1]]|0.402|
|[[:human genes:i:ints5|INTS5]]|0.402|
|[[:human genes:s:sf3a3|SF3A3]]|0.402|
|[[:human genes:s:scaf1|SCAF1]]|0.402|
|[[:human genes:c:ccdc116|CCDC116]]|0.4|
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 154/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|5/28|
|blood|12/28|
|bone|8/25|
|breast|8/33|
|central nervous system|15/56|
|cervix|0/4|
|colorectal|1/17|
|esophagus|1/13|
|fibroblast|1/1|
|gastric|4/15|
|kidney|8/21|
|liver|6/20|
|lung|10/75|
|lymphocyte|9/14|
|ovary|6/26|
|pancreas|2/24|
|peripheral nervous system|2/16|
|plasma cell|6/15|
|prostate|0/1|
|skin|6/24|
|soft tissue|1/7|
|thyroid|0/2|
|upper aerodigestive|3/22|
|urinary tract|9/29|
|uterus|1/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 1518
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 7.11 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='CTR9 Expression in NALM6 Cells: 7.11'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>